Home > Haematology > Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Phase 3 GLOW: first-line ibrutinib plus venetoclax improves outcomes in elderly or unfit CLL

Expert
Dr. Talha Munir, Leeds Teaching Hospitals NHS Trust, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 3, GLOW
With an updated median follow-up of 34.1 months, the 30-month progression-free survival (PFS) was 80.5% with ibrutinib plus venetoclax versus 35.8% for chlorambucil plus obinutuzumab in elderly or unfit patients with chronic lymphocytic leukaemia (CLL) in the first line. These new findings evaluating the efficacy and safety of ibrutinib plus venetoclax as a potential fixed-duration treatment in adult patients were presented at the American Society of Hematology (ASH) annual meeting, held in Atlanta, Georgia from 11-14 December, 2021. Medicom spoke with Dr. Talha Munir (Leeds Teaching Hospitals NHS Trust, UK) who presented these results [1].


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on